Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.46 |
| ▸ | F13A1 | P00488 | 11/20 | 0.46 |
| ▸ | TGM1 | P22735 | 8/20 | 0.46 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17293254 | 0.85 | STS (0.48) | STSMAPTGPR119 | |
| SCHEMBL22606389 | 0.85 | CXCR2 (0.41) | TGM2F13A1TGM1STSPOLB | |
| SCHEMBL17293329 | 0.85 | STS (0.41) | TGM2F13A1TGM1STSGPR119 | |
| SCHEMBL17293347 | 0.85 | STS (0.41) | STSPOLBMEN1KMT2AGPR119 | |
| SCHEMBL19082732 | 0.84 | STS (0.46) | STSMAPTMEN1KMT2AGPR119 | |
| SCHEMBL1563090 | 0.83 | POLB (0.45) | POLBMAPTMEN1KMT2A | |
| SCHEMBL17293485 | 0.83 | ALDH1A1 (0.40) | POLBMAPTMEN1KMT2A | |
| SCHEMBL2771302 | 0.82 | NAMPT (0.43) | KMT2A | |
| SCHEMBL12662260 | 0.82 | STS (0.44) | STSMAPTMEN1KMT2AGPR119 | |
| SCHEMBL17293323 | 0.82 | TSHR (0.41) | POLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-02 | — | — | US | disclosed |
| US-20190010135-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| US-10106515-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-23 | — | — | US | disclosed |
| EP-3148963-B1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-13 | — | — | EP | disclosed |
| EP-3148963-B1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-06-13 | — | — | EP | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
| EP-3148963-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181186-A1 | 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| EP-1272175-B1 | N,N'-DIARYL GUANIDINES AS IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-1351933-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060084641-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| EP-1351933-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040048897-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
| US-6680317-B2 | N-(PHENYL)-N*-(2-HYDROXY-3-AMINOSULFONYLPHENYL)GUANIDINE DERIVATIVES; CHEMOKINE INHIBITORS; RESPIRATORY, CARDIOVASCULAR, RHEUMATIC, BRAIN, AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-01-20 | — | — | US | disclosed |
| US-20030216375-A1 | Il-8 receptor anatagonists | GLAXOSMITHKLINE LLC | 2003-11-20 | — | — | US | disclosed |
| EP-1351933-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057230-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106515-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | TGM2 3636/4885F13A1 4150/4885TGM1 3737/4885 |
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | TGM2 3529/4885F13A1 4127/4885TGM1 3650/4885 |
| US-20030216375-A1 | Il-8 receptor anatagonists | CXCL8, CCR8, IL1R1 | TGM2 2321/4885F13A1 486/4885TGM1 1957/4885 |
| US-20040048897-A1 | Il-8 receptor antagonists | CXCL8, CCR8, TLR8 | TGM2 2325/4885F13A1 797/4885TGM1 2546/4885 |
| US-10336719-B2 | 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | TGM2 3547/4885F13A1 4170/4885TGM1 3656/4885 |
| US-20060084641-A1 | IL-8 receptor antagonists | CXCL8, CCR8, TLR8 | TGM2 2325/4885F13A1 797/4885TGM1 2546/4885 |
| US-20190010135-A1 | Novel Compounds | CXCR2, CXCR1, CXCR3 | TGM2 3007/4885F13A1 4344/4885TGM1 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.